Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 16,142 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Kidney Cancer, Melanoma (Skin)
Interventions: computed tomography, positron emission tomography, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dermatomyositis
Interventions: KYV-101; Biological
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 72 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Breast Cancer
Interventions: Dasatinib and Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: PEAK PlasmaBlade, Traditional Electrosurgery with scalpel; Device · Procedure
Lead sponsor: Medtronic Surgical Technologies; Industry
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Mountain View, California

Conditions: Pruritis
Interventions: Sarna, Cetaphil; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Systemic Sclerosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more

Conditions: Relapsed Breast Cancer, Neoplasms, Breast
Interventions: Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more

Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography; Dietary Supplement · Other · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin hydrochloride; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 2,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 134
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 84 more

Conditions: Melasma
Interventions: Illuminate Cream; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: Joseph Baar, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: tofacitinib 5mg po bid; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Homocystinuria
Interventions: taurine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 49 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 4
States / cities: Aurora, Colorado • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Skin Cancer
Interventions: Ultraviolet B Radiation, No Ultraviolet B Radiation; Radiation · Other
Lead sponsor: Wright State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Solid Tumor
Interventions: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 12 Years and older
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: hominex-2; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acne
Interventions: Product A, Product B; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Herpes Simplex, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
Interventions: Mindfulness Based Stress Reduction (MBSR), Control; Behavioral · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Breast Cancer, Breast Cancer
Interventions: Neratinib, Lapatinib, Capecitabine; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 44
States / cities: Tucson, Arizona • Murrieta, California • Orange, California + 40 more

Conditions: Dermatitis, Nevus, Psoriasis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 36
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 30 more

Conditions: Melanoma (Skin)
Interventions: Shade + app with messaging, Shape + app without messaging; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Combination Chemotherapy in Treating Women With Breast Cancer

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients

Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine

DNA Repair Activity in the Skin of Day and Night Shift Workers

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer

A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments

An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

Mindfulness Based Stress Reduction in Rheumatic Diseases

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors